NEWA® was created by EndyMed, a medical aesthetic company that offers energy-based aesthetic treatment systems for both the professional and consumer markets. EndyMed’s innovative, FDA cleared 3DEEP® RF technology is a clinically proven, effective solution for wrinkle reduction. 3DEEP® delivers focused energy deep into the dermis, providing safe treatments. 3DEEP® RF technology has been used in thousands of treatments by dermatologists, plastic surgeons and skin rejuvenation clinics worldwide.
EndyMed’s clinically proven 3DEEP® technology delivers focused RF energy 3 layers deep into the skin to reduce the appearance of wrinkles. EndyMed has taken the same 3DEEP® technology which powers its medical/professional treatment systems and has adapted it for NEWA®, so consumers can enjoy 3DEEP® treatments in the comfort and convenience of their home.
EndyMed consistently invests in clinical studies to ensure that the 3DEEP® RF technology that powers both the professional and consumer lines is the most effective and safest available today. With over 30 published peer-reviewed studies by international-renowned dermatologists and plastic surgeons, EndyMed is very proud to offer our clients the next level in the evolution of RF technology.
69 participants (average age 54.3 years; 37-72 years old). Treatments were performed 5 times a week for three weeks, with a follow up evaluation after 3 months (without further treatment). 41 participants, with an average age of 57 (range of 39-77 years).
Objective assessments were performed according to the Fitzpatrick’s Wrinkle and Elastosis Grading Scale by three impartial Dermatologists.
Methods used: expert assessment, image analysis, Cutometer, Siascope.
Statistically significant results at the 12 week follow-up:
Comments from study participants at the 4 week follow up:
17 users participated in this study (two groups of 8 and 9 participants respectively, average age of 58.52 (51-64))
Reduction of wrinkle severity:
Jaw line lift at 12 weeks:
Objective Siascope measurement:
IRB approved, 60 participants were tested for a duration of 6 weeks. The original patch sites exhibited no reactions during the induction phase and the rest period. No other reactions were noted.